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Background: PPAR agonists improve insulin sensitivity but also evoke weight gain.
Results: GQ-16 is a PPAR partial agonist that blocks receptor phosphorylation by Cdk5 and improves insulin sensitivity in
diabetic mice in the absence of weight gain.
Conclusion:Theunique bindingmode ofGQ-16 appears to be responsible for the compound’s advantageous pharmacological profile.
Significance: Similar compounds could have promise as anti-diabetic therapeutics.
The recent discovery that peroxisome proliferator-activated
receptor  (PPAR) targeted anti-diabetic drugs function by
inhibiting Cdk5-mediated phosphorylation of the receptor has
provided a new viewpoint to evaluate and perhaps develop
improved insulin-sensitizing agents. Herein we report the
development of a novel thiazolidinedione that retains similar
anti-diabetic efficacy as rosiglitazone in mice yet does not elicit
weight gain or edema, common side effects associated with full
PPAR activation. Further characterization of this compound
shows GQ-16 to be an effective inhibitor of Cdk5-mediated
phosphorylation of PPAR. The structure of GQ-16 bound to
PPAR demonstrates that the compound utilizes a binding
mode distinct from other reported PPAR ligands, although it
does share some structural features with other partial agonists,
such as MRL-24 and PA-082, that have similarly been reported
to dissociate insulin sensitization from weight gain. Hydrogen/
deuterium exchange studies reveal that GQ-16 strongly stabi-
lizes the -sheet region of the receptor, presumably explaining
the compound’s efficacy in inhibiting Cdk5-mediated phos-
phorylation of Ser-273. Molecular dynamics simulations sug-
gest that the partial agonist activity of GQ-16 results from the
compound’s weak ability to stabilize helix 12 in its active con-
formation. Our results suggest that the emergingmodel, whereby
“ideal” PPAR-based therapeutics stabilize the -sheet/Ser-273
region and inhibit Cdk5-mediated phosphorylation while mini-
mally invokingadipogenesisandclassicalagonism, is indeedavalid
framework to develop improved PPAR modulators that retain
antidiabetic actions whileminimizing untoward effects.
As the prevalence of obesity continues to rise, therapies to
treat metabolic syndrome and its associated conditions are of
increasing importance. Thiazolidinediones (TZDs),8 such as
pioglitazone and rosiglitazone, are synthetic insulin-sensitizing
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drugs that are highly effective in treating insulin resistance and
type 2 diabetes (1). Unfortunately, the use of TZDs has been
beset by insidious side effects, including weight gain, edema,
cardiovascular toxicity (2), and bone loss (3). The Food and
Drug Administration recently restricted the use of rosiglita-
zone due to an increased risk of cardiovascular events, under-
scoring a need for new medications that achieve insulin sensi-
tization without adverse cardiovascular effects.
TZDs are potent agonists of PPAR, a transcription factor
and nuclear hormone receptor that is often referred to as the
master regulator of adipogenesis (4–6). The classical mecha-
nism by which TZDs activate PPAR is well established (7).
Ligand binding induces a large conformational change in helix
12 of the ligand-binding domain (LBD) of the receptor (8). This
remodeling of the LBD creates a hydrophobic cleft on the
surface of the receptor that serves as a high affinity docking
site for the recruitment of transcriptional coactivators.
Although the mechanism of transcriptional activation may
be well appreciated, the rationale for insulin sensitization
has not been. First, why is the activation of a pro-obesogenic
receptor beneficial in treating insulin resistance, a phenom-
enon closely linked to obesity? Further, significant efforts
toward the development of PPAR ligands have failed to
demonstrate a clear correlation between receptor transcrip-
tional activation and in vivo efficacy. In fact, one of the most
tantalizing results of these efforts may have been the discov-
ery of “partial agonists,” ligands with only partial efficacy in
activating PPAR that maintain insulin-sensitizing actions.
That many partial agonists were reported to have lesser side
effects than the full agonist TZDs suggested that ligands
could be developed that maintain the insulin sensitization of
TZDs without the undesirable side effects; however, the
rationale for doing so was unclear.
Recently, however, studies from Choi et al. (9) have shown
that PPAR phosphorylation at Ser-273 is linked to obesity and
insulin resistance. Ser-273 phosphorylation results in the dys-
regulation of a subset of PPAR target genes, such as adiponec-
tin, that are known to be associated with insulin sensitization.
Moreover, this study also suggested that both TZDs and partial
agonists with anti-diabetic effects improve insulin sensitivity
primarily by inhibiting Cdk5-mediated phosphorylation of
PPAR at Ser-273. Ser-273 phosphorylation seems to be dis-
tinct from classical transcriptional activation, which appears to
mediate at least some of the undesirable side effects of chronic
PPAR activation.
Herein we report the development of a novel PPAR-tar-
geted ligand that displays robust anti-diabetic activity in mice
yet is dissociated from the TZD-related side effects of weight
gain and edema. Structural and biochemical analyses allowed
us to relate ligand bindingmode to the desirable pharmacology
and suggest that the in vivo efficacy of this compound arises
from its ability to selectively and strongly stabilize the -sheet
region of the receptor, thus inhibiting Ser-273 phosphorylation
by the Cdk5 kinase, as originally proposed by Choi et al. (9).
These results may assist in the development of novel PPAR




in a manner similar to that previously described (10). Pioglita-
zone, troglitazone, bezafibrate, and 9-cis-retinoic acid were
from Sigma, and rosiglitazone was from Cayman Chemical
(Ann Arbor, MI). Pioglitazone, troglitazone, and rosiglitazone
were sequentially used as positive controls for PPAR activation
due to availability issues. Anti-aP2, anti-GAPDH, HRP-conju-
gated anti-mouse, and anti-goat IgGs were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). [3H]rosiglita-
zone was from American Radiolabeled Chemicals (St. Louis,
MO).
Transactivation Assays—Human promonocyte U-937 cells
were transiently cotransfected with a plasmid containing the
PPAR LBD fused to the Gal4 DNA-binding domain and a
plasmid containing the luciferase reporter gene under regula-
tion by five Gal4 DNA-binding elements (UASG 5 TK-lucif-
erase). Transfections were performed by electroporation, and
cells were treated with vehicle (DMSO) or compounds for 24 h
at 37 °C. A reporter luciferase assay kit (Promega) was used to
measure luciferase activity according to the manufacturer’s
instructions, with a luminometer (Turner). Each experiment
was performed in triplicate and repeated at least three times.
Results were reported as -fold induction of normalized lucifer-
ase activity S.E.
PPAR Competition Binding Assay—His-LBD-hPPAR was
incubated for 12 h at 4 °Cwith 40 nM [3H]rosiglitazone (specific
activity 50 Ci/mmol) in buffer containing 10 mM Tris, pH 8.0,
50 mM KCl, and 10 mM dithiothreitol, in a final volume of 100
l. Vehicle or unlabeled ligandswere then added and allowed to
incubate for an additional 12 h at 4 °C. Bound radioactive ligand
was separated from free radioactivity by gravity flow-through
1-ml SephadexG-25 desalting columns and quantitated using a
liquid scintillation counter. Ki values were calculated using
the one-site competition model in GraphPad 4.0 software
(GraphPad, San Diego, CA). Similar methods were used ini-
tially to determine theKd value of [3H]rosiglitazone to be 33 nM.
Coactivator Interaction Assay—Full-length PPAR was
labeledwith [35S]methionine using a coupled in vitro transcrip-
tion/translation system (Promega). GST and GST-SRC1(381–
882) were expressed in Escherichia coli BL21 cells and purified
using glutathione-Sepharose 4B beads. The interaction reac-
tion was carried out as follows. Three ml of [35S]methionine-
labeled PPAR were incubated with the glutathione bead sus-
pension containing 4mgofGSTorGST-SRC1 fusion protein in
GST-binding buffer (1 TST buffer with 0.1% Nonidet P-40,
0.1% Triton X-100, 1 mM DTT, and 2 g/ml bovine serum albu-
min) in the presence of vehicle or the indicated ligands in a final
volume of 150ml. After 2 h on a nutator at 4 °C, the beads were
washed three times with 1 ml of GST-binding buffer. Bound
proteins were eluted in 2 SDS loading buffer and resolved
in 10% SDS-PAGE. After electrophoresis, the gels were fixed in
10% acetic acid (v/v), 40% methanol (v/v) for 30 min; treated in
Amplify (Amersham Biosciences) for 30 min; and dried under
vacuum for 2 h at 80 °C. Labeled PPARwas then visualized by
autoradiography.
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Adipocyte Differentiation Assay, Oil Red O Staining, and
Immunoblotting—Murine mesenchymal C3H10T1/2 cells or
mouse embryonic fibroblast NIH-3T3L1 cells were cultured in
DMEM supplemented with 10% fetal bovine serum, 2 mM glu-
tamine, 50 units/ml penicillin, and 50 g/ml streptomycin and
maintained at 37 °C and 5% CO2. Two-day postconfluent cells
(day 0)were induced to differentiate by incubationwithDMEM
supplementedwith 1g/ml insulin (Sigma), 0.5mM 3-isobutyl-
1-methylxanthine (Sigma), and 1 M dexamethasone (Sigma)
for 2 days, followed by incubation with medium supplemented
with 1 g/ml insulin for 2 days. After this, cells were main-
tained in cell culture medium, changed every second day,
until processing for analysis. Vehicle, 10mM rosiglitazone, or
10 mM GQ-16 was added to the medium throughout the
differentiation period (from day 0 to 2). Adipogenesis was
assessed by staining intracellular lipids with Oil Red O, as
described (11), and by immunoblotting for the adipocyte-
specific marker aP2.
Mouse Protocols and Western Blots of Insulin Signaling
Pathways—The ethics committee of the University of Campi-
nas approved all animal protocols. Male Swiss mice were
obtained from the University of Campinas Central Animal
Breeding Center. Twelve-week-old mice that had been fed a
high fat diet consisting of 55% calories from fat, 29% from car-
bohydrate, and 16% from protein (produced by the University
of Campinas Central Animal Breeding Center; supplemental
Table 1) since the age of 4 weeks were randomly assigned to
receive vehicle, rosiglitazone (4 mg/kg/day), or GQ-16 (20
mg/kg/day) by oral gavage daily (n  6/group). After 10 or 12
days of treatment, mice were submitted to either an insulin
tolerance test (ITT) or intraperitoneal glucose tolerance test,
respectively. All mice were weighed at 12 days. For the ITT, 1.5
IU/kg of human recombinant insulin (Humulin R) from Lilly
was injected intraperitoneally, and serum glucose was mea-
sured at 0, 5, 10, 15, 20, 25, and 30 min thereafter. Glucose
disappearance rate (Kitt) was calculated as described previously
(12). For the intraperitoneal glucose tolerance test, glucose was
administered intraperitoneally at a dose of 1 g/kg body weight,
and serum glucose was measured at 0, 15, 30, 60, 90, and 120
min. After 15 days, mice were anesthetized by intraperitoneal
injection of sodium thiopental, and anesthesia was confirmed
by the loss of pedal and corneal reflexes. Insulin was then
injected (3.8 IU/kg intravenously), and 5min later, muscle, adi-
pose tissue, and liver extracts were used for immunoblotting
with the following antibodies: anti-insulin receptor, anti-phos-
phorylated insulin receptor, anti-insulin receptor substrate 1,
anti-phosphorylated insulin receptor substrate 1, anti-JNK
(Santa Cruz), anti-protein kinase B, anti-phosphorylated pro-
tein kinase B, and anti-IB (Cell Signaling).
Energy Balance Studies—Male C57Bl/6J mice at 6 weeks of
age were fed a Western diet (45% kcal fat, D12079, Research
Diets) for 10 weeks. Metabolic rate, food intake, and ambula-
tory activity were measured using the comprehensive labora-
tory animal monitoring system from Columbus Instruments
(Columbus, OH). Mice were housed in individual metabolic
cages with food and water ad libitum and allowed to acclimate
for 48 h prior to the start of data collection. Mice were admin-
istered vehicle, rosiglitazone (4 mg/kg/day), or GQ-16 (20
mg/kg/day) via intraperitoneal injection. Energy expenditure,
food intake and ambulatory activity were examined and
reported as an average over 3 days. After 7 days, fat and lean
body mass were measured by quantitative NMR, and hemato-
crit levels were measured following capillary centrifugation.
Cdk5 Phosphorylation of PPAR LBD—Purified PPAR LBD
was bound to HisTrap magnetic beads (Invitrogen) and incu-
bated with active Cdk5 p35 (Sigma) in 70 mM Tris, pH 7.6, 10
mM MgCl2, 5 mM DTT, and 1 M ATP for 1 h, after which the
beads were washed three times with wash buffer, containing 20
mM Tris, pH 8, 150 mM NaCl, and 0.1% Triton X-100. Proteins
were resolved by SDS-PAGE, and PPAR phosphorylation was
assessed by autoradiography.
Protein Preparation and Crystallization—The N-terminal
His6-tagged PPAR LBD construct was transformed into BL21
cells grown in LB at 37 °C to an OD of 0.6. Expression was
induced with 0.5 mM isopropyl 1-thio--D-galactopyranoside,
and cells were grown at 18 °C overnight. Cells were harvested
by centrifugation, lysed via sonication, and purified using a GE
Hiprep Ni2-NTA affinity column via the manufacturer’s
standard protocol and eluted with 500mM imidazole. The frac-
tion containing pure PPARLBDwas buffer-exchanged into 25
mM Tris buffer at pH 7.5 containing 150 mM NaCl using a
desalting column. The proteindrug complex was prepared by
adding a saturated solution ofGQ-16 inDMSO to a 1:2 PPAR-
LBD/SRC1-peptide (LTERHKIL-HRLLQEGSPS) solution. Af-
ter mixing, the final concentration of GQ-16 was 600 mM.
The complex was incubated at room temperature overnight
and then concentrated to a final protein concentration of 10
mg/ml. The proteinligand complex was crystallized at room
temperature using the hanging drop vapor diffusionmethod by
mixing equal volumes of the above complex and the reservoir
solution containing 0.2 M ammonium acetate, 0.1 M sodium
citrate at pH 5.6, and 30% PEG 4000. X-ray data were collected
at the Advanced Light Source (ALS) Beamline 5.0.1. Data pro-
cessing and scaling was done using IMOSFLM and SCALA
module in CCP4 (13), and the structure was refined via the
PHASER molecular replacement (14) module in PHENIX (15)
to 2.1 Å. Coot (16) was used to visualize experimental electron
density maps and for model building. Selected intensity data
and refinement statistics are given in supplemental Table 2. All
figures were prepared using PyMOL software (Schrödinger
LLC, New York).
Hydrogen/DeuteriumExchangeMass Spectrometry of PPAR
LBD—Mass spectroscopy experiments were conducted using
apo-hPPAR LBD and hPPAR LBD in the presence of rosigli-
tazone andGQ-16 (1.5-foldmolar excess of ligand). Hydrogen/
deuterium exchange mass spectrometry experiments were ini-
tiated by 20-fold dilution of hPPAR inD2Obuffer (final buffer:
1mMHepes, 7.5mMNaCl, 0.2% glycerol, 0.1mMDTT, and 60%
(v/v) D2O) at 25 °C. These mixtures were incubated for 0, 1, 5,
30, and 90 min. Hydrogen/deuterium exchange was halted at
each time point by placing samples on ice and adding 10 mM
phosphate buffer (pH 2.5). The protein was immediately sub-
mitted to cleavage with pepsin (10 g) for 7 min at 4 °C to
decrease the rate of solvent back-exchange. After the addition
of 30% acetonitrile, the samples were immediately applied onto
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a Synapt G2 HDMS (Waters) by direct infusion. The software
MS-Digest (17) was used to identify the sequence of the peptic
peptide ions, generated by pepsin cleavage. Deuterium level for
each peptide was determined from the differences in centroid
masses between the deuterated and non-deuterated fragments
(18). The non-digested protein, after deuteration, was used as a
control to estimate deuterium loss during protein digestion.
This procedure was applied to both liganded and unliganded
protein.
Molecular Dynamics Simulations—The simulations started
from the crystallographic structure presented in this work
(chain B of the GQ-16 complex) and from the structure 1FM6
(19) (chainDof the rosiglitazone complex) from the PDB.Miss-
ing residues in the GQ-16 complex structure (206–209 and
258–276) were taken from the structure of the rosiglitazone
complex, which fit well after structural alignment with
LovoAlign (20). Hydrogen atoms were added, and the proton-
ation states of the histidine residues were estimated with H
(21) at pH 7. For all of the neutral histidines, the position of the
hydrogen atoms was defined in such a way as to favor hydrogen
bonds. The systems were then fully solvated with a water shell
of at least 15 Å and neutralized with sodium and chloride ions
to a total concentration of 0.15 mol/liter using the vmd (22)
plugins solvate and autoionize, respectively. The final systems
contained around 58,000 atoms.
The CHARMM force field (23) was used for the protein, and
the TIP3P (24) model was used for water molecules. Force field
parameters for rosiglitazone were obtained as described previ-
ously (25), and GQ-16 was parameterized consistent with this
protocol. The simulations were performed using periodic
boundary conditions in the NpT ensemble 300 K and 1 atm
using the Langevin thermostat and the Langevin/Nosé-Hoover
piston for the temperature and pressure control, respectively.
Electrostatics was evaluated using the particle mesh Ewald (26)
algorithm, and short range interactionswere truncated at a cut-
off radius of 12 Å. All of the bonds involving apolar hydrogens
were constrained at their equilibrium values using SHAKE (27),
and a time step of 2.0 fs was used for the integration of the
equations of motion.
The following treatment was used to prepare the systems
for the production runs: (a) 2000 energy minimization steps
using the conjugate gradients algorithm (CG) followed by
200 ps of MD keeping the ligand and protein residues fixed,
except modeled residues; (b) 1000 energy minimization
steps using CG followed by 200 ps of MD keeping only 
carbons fixed (except those modeled); (c) 600 ps of MDwith-
out any constraints. After these preparative steps, MD tra-
jectories of 5.0 ns were generated for analysis. This protocol
was repeated five times for each system using the program
NAMD (28).
Statistical Analysis—Data handling, analysis, and graphical
representations were performed using GraphPad 4.0 software
(GraphPad, San Diego, CA). Statistical differences were deter-
mined by one-way analysis of variance followed by Student-
Newman-Keuls multiple comparison or by Student’s t test; p
0.05 was accepted as statistically significant.
RESULTS
GQ-16 Is Partial Agonist of PPAR with Reduced Adipogenic
Actions—We previously described a series of 5-benzylidene-4-
(4-methyl-benzyl)-thiazolidine-2,4-dione derivatives substi-
tuted on the benzylidene moiety (29) that included the ligand
GQ-2. As an extension of this effort we synthesized the related
compound GQ-16 (Fig. 1). GQ-16 was found to be a moderate
affinity ligand for the LBD of PPAR, exhibiting a Ki of 160 nM
(supplemental Fig. S1A). GQ-16 was specific for PPAR and
possessed no detectable activity when tested for the ability to
activate other PPAR subtypes (PPAR or PPAR/) or RXR
(supplemental Fig. S1B). In transactivation assays, GQ-16 acted
as a weak partial agonist. Even high concentrations of GQ-16
elicited only approximately one-third of themaximal activation
stimulated by rosiglitazone (Fig. 2A). In vitro binding studies
performed in the presence of saturating concentrations of
ligand demonstrated that GQ-16 is significantly less effective in
promoting the interaction between PPAR and SRC-1 than the
TZD troglitazone (supplemental Fig. S2). Finally, GQ-16 dis-
played reduced adipogenic potential in both NIH-3T3 and
C3H10T1/2 cells, established models of PPAR-dependent
adipogenesis. Intracellular lipid accumulation afforded by
GQ-16 and induction of the adipocyte-specific marker aP2 was
less than that obtained with rosiglitazone (Fig. 2, B andC). Col-
lectively, these results suggest that the binding of GQ-16 to
PPAR induces a receptor conformation that is suboptimal for
the recruitment of coactivators to the AF-2 surface of the
receptor.
GQ-16 Improves Insulin Sensitivity without Promoting
Weight Gain—We next tested the anti-diabetic properties of
GQ-16 in a mouse model of diet-induced obesity and insulin
resistance and compared its effects to rosiglitazone. Both
FIGURE1.Chemical structureofGQ-16comparedwithTZDs rosiglitazone
and pioglitazone.
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GQ-16 and rosiglitazone reversed high fat diet (HFD)-medi-
ated impairments in insulin signaling as indicated by an
increase in phosphorylation of the insulin receptor (IR; Fig. 3,
A–C), insulin receptor substrate 1 (IRS-1; Fig. 3,D–F), and pro-
tein kinase B (Akt; Fig. 3,G–I) in adipose tissue, liver, and mus-
cle. GQ-16 and rosiglitazone also exhibited equivalent capacity
to block HFD-dependent effects on intracellular inflammatory
pathways related to insulin resistance. Both ligands reversed
HFD-dependent suppression of inhibitor of nuclear factor B
(IB) protein in the adipose tissue, liver, and muscle of HFD-
fed mice when compared with chow-fed controls (Fig. 3, J–L).
Further, GQ-16 and rosiglitazone reduced HFD-dependent
phosphorylation of JNK, a marker of inflammatory signaling in
adipose tissue, liver, and muscle (Fig. 3, M–O). Remarkably,
although GQ-16 treatment resulted in improved insulin sensi-
tivity, as indicated by a greater plasma glucose disappearance
rate (Kitt) (Fig. 4A), and glucose tolerance (Fig. 4B), GQ-16 did
not elicit increased weight gain (Fig. 4C), a common side effect
of TZD treatment.
Unlike Rosiglitazone, GQ-16 Does Not Induce Edema—In
order to establish how GQ-16 acts as a PPAR agonist without
evoking the associated side effect of weight gain, we sought to
determine which aspects of energy balance and contributing
factors to weight gain might be differentially regulated by
GQ-16 and rosiglitazone. Because rosiglitazone is known to
stimulate weight gain via two primary mechanisms (hyperpha-
gia, which has recently been shown to have a neurological basis
(30, 31), and edema, which is mediated by a PPAR-driven
increase in water retention by the kidneys (32)), we examined
the effects of rosiglitazone and GQ-16 on food intake and
hemodilution. Treatment with either rosiglitazone or GQ-16
for 7 days did not alter food intake (Fig. 4D) or activity and did
not result in a detectable change in body composition (supple-
mental Fig. S3), although there was a statistically significant
difference representing decreased fat mass in GQ-16-treated
mice relative those treated with rosiglitazone. Conversely,
treatmentwith rosiglitazone brought about a significant level of
hemodilution, whereas hematocrit was unchanged following
GQ-16 treatment (Fig. 4E). In addition to hyperphagia, recent
studies have shown that PPAR agonists can also affect energy
balance in a positive fashion by increasing the oxidative metab-
olism, or inducing a “beiging,” of white adipose tissue (WAT)
(33). To examine whether GQ-16 brought about a beiging of
WATor increased energy expenditure by othermeans, indirect
calorimetry was used to measure metabolic rate, and the
expression of oxidative metabolic genes was measured in vis-
ceral and subcutaneous WAT as well as brown adipose tissue.
Neither rosiglitazone nor GQ-16 afforded a detectable increase
in energy expenditure (Fig. 4, F and G), and genes involved in
the oxidative metabolism of adipose tissue were not signifi-
cantly changed in either epididymal or inguinalWAT or brown
adipose tissue (supplemental Fig. S4). However, several mark-
ers of oxidative metabolism in subcutaneous inguinal fat, such
as Ucp1, Elovl3, and Pgc-1a, did tend to increase following
treatment with either rosiglitazone or GQ-16, although high
variability of the expression data precludes detailed analysis.
Consequently, we cannot rule out the possibility that GQ-16
may exert its effects in part by increasing the oxidative metab-
olism of subcutaneousWAT. Thus, althoughGQ-16 appears to
be a weak PPAR agonist relative to rosiglitazone, it possesses
efficient insulin-sensitizing actions in vivo that are separable
from at least one of the deleterious effects of the TZDs, edema,
and it may have additional beneficial effects on WAT
metabolism.
GQ-16 Inhibits Cdk5 Phosphorylation of PPAR Ser-273—
Because the insulin-sensitizing effects of PPAR ligands, such
as rosiglitazone, appear to bemore closely correlated with their
ability to inhibit phosphorylation of Ser-273 than with classical
receptor activation, we assessed the ability of GQ-16 to inhibit
Cdk5 phosphorylation of PPAR in vitro. GQ-16 blocked Ser-
273 phosphorylation in a concentration-dependent fashion,
with higher concentrations being as efficacious as rosiglitazone,
affecting a complete inhibition of PPAR phosphorylation (Fig.
4H).
X-ray Structural Analysis Reveals Unique GQ-16 Binding
Mode Relative to TZDs and Other PPAR Ligands—To better
understand the structural basis for the unique pharmacologic
profile of GQ-16, we determined the x-ray crystal structure of
the GQ-16PPAR complex. In general, the complex appeared
similar to previously reported structures of liganded PPAR
structures, with helix 12 in an active position and no notewor-
thy differences in overall LBD fold (Fig. 5,A andB). There were,
however, significant differences in ligand bindingmode.GQ-16
was found to bind to PPAR in a fashion that is not only distinct
from the binding mode of TZDs, such as rosiglitazone, but
appears to be unique relative to nearly all other previously
reported PPAR structures (Fig. 5C). Although TZDs, such as
rosiglitazone and pioglitazone, bind in a perpendicular fashion
to helix 3, partially wrapping around the helix, GQ-16 binds in
a north-south orientation, parallel to helix 3. Given this binding
modality, GQ-16 does not make direct contact with any resi-
dues of helix 12 (Fig. 5D), a suggested hallmark of full agonists,
FIGURE 2. GQ-16 is a partial agonist of PPAR with modest adipogenic
activity. A, in vitro transactivation of a PPAR-based reporter with either
rosiglitazone (squares) or GQ-16 (triangles). B and C, GQ-16 (10 M) induces
adipogenesis to a lesser extent than rosiglitazone (Rosi; 10 M) in both
C3H10T1/2 (B) and NIH-3T3-L1 cells (C), as indicated by Western blot of the
adipogenic marker protein aP2 (B) and Oil Red staining (C). Error bars, S.E.
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such as the TZDs, which interact with the side chain of Tyr-501
on the inner surface of helix 12 via their TZD core (Fig. 5E).
GQ-16 makes no polar contacts with PPAR; instead, ligand
positioning appears to be mediated by van der Waals interac-
tions, water-mediated contacts, and -stacking between the
guanidinium side chain of Arg-316 and the tolyl group of
GQ-16.
GQ-16 Strongly Stabilizes the -Sheet/Ser-273 and Helix 3
Regions of PPAR—In order to examine whether GQ-16 may
blockCdk5-mediated phosphorylation of Ser-273 by stabilizing
the -sheet region of PPAR, we carried out hydrogen/deute-
rium exchange (HDX) (34) experiments to explore structural
dynamics of the receptor in solution. In the absence of ligand,
helix 12 of the aporeceptor appears to be highly dynamic (Fig. 6
and supplemental Fig. S5), a fact that is well appreciated for
nearly all nuclear receptors. However, high levels of exchange
were not limited to helix 12 but were instead observed through-
out the LBD of the aporeceptor. The lability of this state sug-
gests that the unliganded receptor does not assume a single well
ordered state but is instead “molten” prior to ligand-induced
stabilization. The binding of either rosiglitazone or GQ-16 to
PPAR resulted in significant stabilization throughout the
entire receptor, as indicated by a large decrease in the overall
hydrogen/deuterium exchange (Fig. 6, A and B).
In particular, the helix 3, helix 12, and -sheet regions of
PPAR were most highly affected by ligand binding. Although
FIGURE 3. GQ-16 improves insulin-signaling components in liver, muscle, and adipose tissue of obese Swiss mice. A–C, insulin-induced tyrosine phos-
phorylation of the insulin receptor (IR); D–F, insulin-induced tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1); G–I, insulin-induced serine
phosphorylation of protein kinase B (Akt); J–L, IB protein levels;M–O, phosphorylation of JNK. The results of densitometry were expressed as arbitrary units.
IB, immunoblot; CTL, control. Bars, mean S.E. (error bars).
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FIGURE 5. GQ-16 interacts with PPAR via a distinctive binding mode. A, although GQ-16 (purple) induces an overall structure similar to that of
rosiglitazone (blue, GQ-16PPAR; white, rosiglitazonePPAR) (Protein Data Bank entry 2PRG), GQ-16 binds to PPAR in a different orientation than
traditional TZDs, such as rosiglitazone. GQ-16 makes no direct contacts with residues of helix 12 (shown in red), a hallmark of traditional TZDs. The Cdk5
recognition site, which includes Ser-273, is shown in magenta. B, electron density of GQ-16 (SA-Composite Omit map; Fo  Fc) contoured at 2 s.
C, superposition of GQ-16 and other reported PPARligand complex structures showing that GQ-16 uses a unique binding mode relative to other
ligands. D and E, comparison of ligand-protein contacts between PPAR and GQ-16 (D) or rosiglitazone (E) (polar contacts are shown as dotted lines).
FIGURE 4. GQ-16 improves insulin sensitivity without evoking weight gain and inhibits Cdk5 phosphorylation of PPAR in vitro. Shown are the short
insulin tolerance test (A), intraperitoneal glucose tolerance test (B), and change in body weight (C) of mice treated with either DMSO, rosiglitazone (Rosi) (4
mg/kg/day), orGQ-16 (20mg/kg/day) for 10 (A) or 12days (B andC) (n6). Theeffect of rosiglitazoneandGQ-16on food intake (D) andhematocrit (E) is shown.
F and G, indirect calorimetry of mice treated with either DMSO, rosiglitazone, or GQ-16 for 7 days. G, average heat over a 4-day period (n  4). H, GQ-16
completely blocks phosphorylation of PPAR by Cdk5 in vitro. PCV, packed cell volume. Shown is mean S.E. (error bars). Analysis was by one-way analysis of
variance. *, p 0.05; **, p 0.01; ***, p 0.001.
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both ligands stabilized the overall receptor and helix 12 to a
similar extent, GQ-16 was more effective at protecting the
lower half of the LBD, stabilizing the helix 11–12 loop, helix 3,
and -sheet/Ser-273 regions of PPAR more strongly than
rosiglitazone (Fig. 6, C–E). At most time points, GQ-16 pro-
tected the peptide representing the first -strand/Ser-273
region more strongly than any other region of the LBD, reveal-
ing the potential of the Ser-273 region to act as a regulatory site
and implying that the in vivo efficacy of GQ-16 stems from its
ability to strongly stabilize this region, protecting it not only
from solvent-mediated hydrogen/deuterium exchange but also
from kinase accessibility to Ser-273.
Molecular Dynamics Simulations of Helix 12 Stabilization by
GQ-16 and Rosiglitazone—To better understand differential
effects of rosiglitazone and GQ-16 on PPAR activity and sta-
bility, we performed molecular dynamics (MD) simulations
with the structures of rosiglitazone and GQ-16 bound to
PPAR (Fig. 7). The simulations predicted that rosliglitazone
binds to helix 12 through a direct hydrogen bond with the res-
idue Tyr-501, in accordance with the crystal structure, and the
occurrence of this bond was nearly 100% (Fig. 7, A and C). In
contrast, GQ-16 attempted to recapitulate this interaction via
the introduction of a loose, water-mediated contact with Tyr-
501, which had an occurrence of about 60% during the simula-
tions (Fig. 7, B and C). Correspondingly, there were somewhat
larger fluctuations in the average position of helix 12 when
PPAR was occupied by GQ-16 than with rosiglitazone, indi-
cated by broader and leftward shifted root mean square devia-
tion values (Fig. 7D). However, these differences in root mean
square deviation do not necessarily imply greater solvent acces-
sibility of helix 12 because analysis of helix 12 hydration indi-
cated that an average of 15watermoleculeswere involved in the
solvation of both systems (supplemental Fig. S6).
DISCUSSION
PPAR agonists, such as the TZDs pioglitazone and rosigli-
tazone, have proven efficacious as insulin-sensitizing agents in
humans as well as in animal models of obesity and diabetes.
Despite established therapeutic value, their clinical use is lim-
FIGURE 6. GQ-16 strongly protects the helix 3 and -sheet regions from hydrogen/deuterium exchange. A, comparison of hydrogen/deuterium
exchange levels after 30 min. In the absence of ligand, high levels of exchange are observed throughout the LBD. B, both rosiglitazone and GQ-16 strongly
protect the overall LBD from exchange, although the pattern produced by each is distinct (A). C–E, although both ligands protect helix 12 similarly (C), GQ-16
more strongly protects the -sheet (D) and helix 3 (E) regions from hydrogen/deuterium exchange.
FIGURE 7.Molecular dynamics simulations predict that GQ-16 stabilizes
theactive conformationofhelix 12 less than rosiglitazone.A andB, unlike
rosiglitazone (A), GQ-16 (B) does not directly contact helix 12; instead a water
moleculemediates an interaction between Tyr-501 of helix 12 and a carbonyl
of GQ-16. C, this water-mediated interaction with helix 12 is weaker than the
direct rosiglitazone-Tyr-501 interaction and exists less than 60% of the time
during simulations. Rosiglitazone makes a direct contact with helix 12 via a
hydrogen bond with the hydroxyl group of Tyr-501 (B) that is quite stable as
the bond is maintained 90% of the time during simulations. D, helix 12
samples abroader ensembleof conformationswhenbound toGQ-16 relative
to rosiglitazone (RSG).
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ited by adverse effects, such asweight gain, bone loss (3, 35–37),
and increased cardiovascular risk (2). These limitations spurred
a large effort to produce PPAR targeted therapeutics that
maintain insulin-sensitizing actions but are dissociated from
the deleterious effects. Initially, side effects were thought to
arise from off-target effects, leading to the subsequent develop-
ment of numerous high affinity, high specificity PPAR ago-
nists. As a seeming paradox, increased potency appeared to
maximize not only the insulin-sensitizing effects but also to
amplify the untoward effects. It became evident that the con-
nection between PPAR activation and beneficial anti-diabetic
actions was not straightforward, and efforts instead shifted
toward the promise of partial agonists (38), PPAR-directed
agents that seemed to possess precisely the right magnitude of
receptor agonism.
Under this paradigm of, “a little bit of activity, but not a lot,”
we developed a series ofmodified TZDs and then selected com-
pounds with weak but definitive activity toward PPAR for fur-
ther study. GQ-2 proved to be effective as an orally available
insulin-sensitizing agent (29) that did not induce weight gain.
Although poor solubility of GQ-2 confounded cellular and bio-
chemical studies, the closely related ligandGQ-16was found to
have similar efficacy in vivo, so further characterization efforts
focused on GQ-16.
Although we initially assumed that GQ-16 simply possessed
a better balance of agonism and antagonism than traditional
TZDs, recent work by Choi et al. (9, 39) suggested a novel,
mechanistic explanation for the insulin-sensitizing actions of
PPAR partial agonists, forcing us to reevaluate the rationale
for our success. The authors provide evidence that the insulin-
sensitizing effects of TZDs are not related to classical agonist
activity but are consequences of a second effect, the ligand-de-
pendent inhibition of Ser-273 phosphorylation by the Cdk5
kinase. This inhibition enhances insulin sensitivity by reversing
Cdk5-mediated attenuation of a subset of beneficial PPAR-
regulated genes, including the adipokine adiponectin (40). Ser-
273, which is located immediately adjacent to the first -strand
of PPAR, is far removed from the AF-2 activation surface.
Intriguingly, the -sheet region has been shown to mediate
interprotein contacts between PPAR and its heterodimeric
partner, RXR (41).Mutation to this region decreases the affinity
of the PPARRXR complex for its response element as well as
reducing its transcriptional activity. Phosphorylation of Ser-273
may similarly disrupt contacts between PPAR and RXR, poten-
tially reducing the transcriptional response from promoters for
which this interaction is constructive. From this new perspective,
the convolution of “partial agonism” arises from PPAR ligands
that are differentially effective in inhibiting the phosphorylation of
Ser-273 relative to their ability to elicit classical AF-2-mediated
activation. Moreover, this model suggests that an “ideal” partial
agonist would block Cdk5 phosphorylation of PPARwhile min-
imally invoking classical activation or adipogenesis.
Is the in vivo efficacy of GQ-16 due to this type of “idealized”
selective PPAR modulation? Although it is difficult to prove
that the positive pharmacological profile of GQ-16 results
solely from the selective inhibition of Cdk5-mediated phos-
phorylation of PPAR, our results are largely consistent with
this model. Even at saturating doses, GQ-16 is significantly less
efficient than TZDs in activating PPAR in transactivation
assays, inducing associationwith coactivators in vitro, and driv-
ing adipogenesis and the expression of adipogenic markers,
such as aP2. Nevertheless, GQ-16 appears to be even more
highly effective than rosiglitazone at stabilizing the helix 3 and
-sheet regions of PPAR and has similar efficacy in blocking
phosphorylation by Cdk5 and improving insulin sensitivity in
vivo, all without invoking attendant weight gain. Taken as a
whole, it appears unlikely that the modest ability of GQ-16 to
initiate transcription via “classical” means is the only factor
responsible for its pharmacological efficacy, which more likely
stems from both its weak classical agonist properties and its
ability to strongly stabilize the -sheet region of PPAR and
occlude Ser-273 from Cdk5 accessibility.
Structural studies indicated that GQ-16 interacts with
PPAR via a binding mode that is unique relative to other
reported PPAR-ligand structures. The positioning of GQ-16
deep in the binding pocket, out of contact with helix 12, utiliz-
ing a north-south binding orientation, bears no resemblance to
the binding mode of TZDs and other full agonists but is most
closely related to partial agonists, such as PA-082 (42),MRL-24,
nTZDpa, and BVT.13 (43). Although the positioning of these
ligands within the binding pocket differs to a certain extent,
none of these ligands interact directly with helix 12. Instead, all
of the compounds bind parallel to helix 3 (supplemental Fig.
S7). Similar to our results with GQ-16, Bruning et al. (43) used
HDX to show that MRL-24, nTZDpa, and BVT.13 all stabilize
the helix 3 and -sheet regions of PPAR even more strongly
than rosiglitazone. Presumably, the binding orientation of these
compounds, which allows for extensive contact between ligand
and helix 3, is responsible for the increased stabilization of this
helix. Ligand binding to PPAR seems to induce a cooperative
folding transition between the helix 3 and -sheet regions
because the stability of these structural elements appears to be
strongly correlated. Because the Cdk5 recognition site extends
into the first -strand of PPAR, structural stabilization of the
-sheet region, elicited by GQ-16 and other ligands, presum-
ably renders Ser-273 inaccessible to the kinase, protecting the
receptor from phosphorylation.
HDX studies indicated that helix 12 exhibits similar solvent
accessibility when the LBD is bound to either GQ-16 or rosigli-
tazone. Thiswas unexpected in light of theweak agonist activity
of GQ-16 and the lack of direct interactions between the ligand
and Tyr-501. Although MD simulations should generally be
treated as suggestive, these simulations can provide useful
insights into conformational changes and other dynamical fea-
tures of a biomolecular systemwhen a good structural model is
available. MD simulations of the GQ-16PPAR complex sug-
gest that GQ-16 uses a bridging watermolecule to interact with
Tyr-501 and that this interaction stabilizes helix 12 sufficiently
that it remains docked with the body of the receptor and is
protected from solvent exposure. However, this water-medi-
ated stabilization is not sufficient to fully secure the active con-
formation of the receptor, leading to suboptimal conforma-
tional restraint of the AF-2 activation surface. Thus, the MD
simulations suggest a potential rationale for the discrepancy
between the HDX results, where GQ-16 appears to stabilize
helix 12 as effectively as rosiglitazone, and the functional stud-
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ies, where GQ-16 is clearly not as efficacious as rosiglitazone at
eliciting classical PPAR activation. If this suggestion is correct,
MD simulation studies may be able to assist in the design of
GQ-16 derivatives that differ in their ability to stabilize helix 12
via this bridging interaction while maintaining their ability to
stabilize the -sheet/S273 region of the receptor.
Although PA-082 and MRL-24 were originally chosen for
comparison with GQ-16 based solely on the similarities of their
ligand binding orientations (supplemental Fig. S7), the pharma-
cological profiles reported for each are remarkably similar to
that of GQ-16. Both are weak agonists of PPAR that have been
reported to act as insulin sensitizers without eliciting weight
gain attendant to rosiglitazone or pioglitazone treatment (42,
44). These similarities suggest a strategy for drug design, and
GQ-16 could represent an attractive lead compound for further
development. Although GQ-16 has only modest affinity for
PPAR, the compound is orally active and displays excellent
insulin-sensitizing actions. Further, the crystallographic struc-
ture of GQ-16PPAR suggests approaches by which to increase
the compound’s affinity and to potentially further separate ligand-
dependent stabilizationof the-sheet/Ser-273 region from that of
helix 12/AF-2. For example, functional groups that improve direct
contacts between GQ-16 and the inner surface of the LBD at the
helix 3/-sheet region could enhance affinity while retaining sta-
bilizing influence on the -sheet region, and strategies to reduce
water-mediated influencesonhelix12may further reduceclassical
partial agonist actions.
It will be important to determine the extent to which com-
plete separation of these effects is possible and desirable.
Although pure PPAR classical agonism appears undesirable,
the extent towhich it is important to completely separate ligand
effects on suppression of Cdk5-dependent phosphorylation at
Ser-273 from helix 12 stabilization remains questionable. Some
amount of adipogenesis may be advantageous; transgenic mice
that overexpress the PPAR target gene adiponectin experi-
ence an expansion of fat mass, which is tied to dramatic
improvements in insulin sensitivity (45). Further studies of par-
tial agonists like GQ-16may help to address this question. Nev-
ertheless, our analysis of the pharmacological profile of GQ-16
lends weight to the conceptual framework for selective PPAR
modulator development proposed by Choi et al. (9, 39). PPAR
ligands that selectively stabilize the -sheet region, shielding
Ser-273 fromCdk5-mediated phosphorylationwhileminimally
invoking classical activation, appear to retain insulin-sensitiz-
ing actions yet display reduced harmful side effects. Continued
efforts toward this endmay lead to the development of effective
insulin sensitizers with improved safety profiles.
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